LivaNova PLC (NASDAQ:LIVN) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC trimmed its position in LivaNova PLC (NASDAQ:LIVN) by 5.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,347 shares of the company’s stock after selling 1,659 shares during the period. Mutual of America Capital Management LLC owned 0.05% of LivaNova worth $1,542,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LIVN. Fifth Third Bancorp increased its holdings in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after purchasing an additional 332 shares during the period. Hexagon Capital Partners LLC increased its holdings in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after buying an additional 370 shares during the period. Lazard Asset Management LLC acquired a new position in LivaNova in the 1st quarter worth approximately $84,000. Canada Pension Plan Investment Board purchased a new position in LivaNova during the 2nd quarter worth approximately $88,000. Finally, Acadian Asset Management LLC acquired a new stake in LivaNova during the 1st quarter valued at approximately $94,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Trading Up 0.8 %

Shares of LIVN stock opened at $51.75 on Tuesday. The stock has a 50 day simple moving average of $52.19 and a 200-day simple moving average of $52.38. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a market cap of $2.81 billion, a price-to-earnings ratio of 123.21 and a beta of 1.01. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Analysts Set New Price Targets

Several research firms have commented on LIVN. Mizuho lowered their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Robert W. Baird upped their target price on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. The Goldman Sachs Group began coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock. Finally, Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, LivaNova currently has an average rating of “Buy” and an average target price of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.